Literature DB >> 8006595

Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism.

S C Lee1, D W Dickson, C F Brosnan, A Casadevall.   

Abstract

Cryptococcus neoformans is an opportunistic fungus that causes life-threatening meningoencephalitis in 5-10% of patients with acquired immune deficiency syndrome. Cryptococcal meningoencephalitis is characterized by a lymphohistiocytic infiltrate, accumulation of encapsulated forms of C. neoformans, and varying degrees of glial reaction. Little is known about the contribution of endogenous central nervous system cells to the pathogenesis of cryptococcal infections. In this study, we investigated the role of astrocytes as potential effector cells against C. neoformans. Primary cultures of human fetal astrocytes, activated with interleukin 1 beta plus interferon gamma inhibited the growth of C. neoformans. The inhibition of C. neoformans growth was paralleled by production of nitrite, and reversed by the inhibitors of nitric oxide (NO.) synthase, NG-methyl-mono-arginine and NG-nitro-arginine methyl ester. The results suggest a novel function for human astrocytes in host defence and provide a precedent for the use of NO. as an antimicrobial effector molecule by human cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006595      PMCID: PMC2191550          DOI: 10.1084/jem.180.1.365

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

Review 1.  Mechanisms of natural resistance to human pathogenic fungi.

Authors:  J W Murphy
Journal:  Annu Rev Microbiol       Date:  1991       Impact factor: 15.500

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 3.  Astrocytes in infectious and immune-mediated diseases of the central nervous system.

Authors:  L Mucke; M Eddleston
Journal:  FASEB J       Date:  1993-10       Impact factor: 5.191

4.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus.

Authors:  A P Lieberman; P M Pitha; H S Shin; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines.

Authors:  S M Levitz; T P Farrell
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

6.  Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity.

Authors:  D L Granger; J R Perfect; D T Durack
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

7.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

8.  Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages.

Authors:  D L Granger; J B Hibbs; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization.

Authors:  E Blasi; R Barluzzi; R Mazzolla; P Mosci; F Bistoni
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

10.  Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

View more
  25 in total

1.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Local nitric oxide production in viral and autoimmune diseases of the central nervous system.

Authors:  D C Hooper; S T Ohnishi; R Kean; Y Numagami; B Dietzschold; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

Review 3.  Inducible nitric oxide synthase in human diseases.

Authors:  K D Kröncke; K Fehsel; V Kolb-Bachofen
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

4.  Inducible nitric oxide synthase in the cardiovascular system.

Authors:  K Bhagat; P Vallance
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

Review 5.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 6.  Infectious immunity in the central nervous system and brain function.

Authors:  Robyn S Klein; Charise Garber; Nicole Howard
Journal:  Nat Immunol       Date:  2017-01-16       Impact factor: 25.606

7.  Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages.

Authors:  L Liu; R P Tewari; P R Williamson
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

8.  Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity.

Authors:  Z Bi; M Barna; T Komatsu; C S Reiss
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas.

Authors:  D Goldman; Y Cho; M Zhao; A Casadevall; S C Lee
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  Biomolecular events involved in anticryptococcal resistance in the brain.

Authors:  E Blasi; R Barluzzi; R Mazzolla; L Pitzurra; M Puliti; S Saleppico; F Bistoni
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.